Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same

• US 5,153,118 A
• Filed: 10/25/1988
• Issued: 10/06/1992
• Est. Priority Date: 12/17/1985
• Status: Expired due to Term

• Current Assignee: Eastern Virginia Medical Authority
• Original Assignee: Eastern Virginia Medical Authority
• Inventors: Wright, George L. Jr., Starling, James J.
• Primary Examiner(s): Saunders, David
• Application Number:
  US07/262,123
• Time in Patent Office: 1,442 Days
• Field of Search: 424/1.1, 424/9, 424/85.8, 424/85.91, 435/7, 435/172.2, 435/240.27, 435/948, 435/7.23, 435/7.9, 436/548, 436/813, 530/387, 530/391, 530/809, 935/107, 935/110
• US Class Current: 424/1.49
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/6861 the tumour determinant being from kidney or bladder cancer cell
• CPC Class Codes: A61K 51/106 the tumor cell being from kidney or bladder
• CPC Class Codes: C07K 16/3038 Kidney, bladder
• CPC Class Codes: Y10S 435/948 using viruses or cell lines
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 530/809 Fused cells, e.g. hybridoma
• CPC Class Codes: Y10S 530/861 involving IgG3, IgG4, IgA, or IgY

Abstract

Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens but not to prostate-specific antigen (PSA) or prostatic acid phosphatase (PAP); and methods of diagnosis and treatment employing the same.

Claims

1. A monoclonal antibody having binding specificity to human prostate tumor-associated membrane antigens that;

(a) does not having binding specificity to prostate-specific antigen, prostatic acid phosphatase, normal lung, lung carcinoma, bladder carcinoma, normal breast, normal liver, breast carcinoma or normal spleen; and

(b) does not have binding specificity to both DU145 and PCP-3.

2. The monoclonal antibody as claimed in claim 1, wherein said monoclonal, antibody is TURP-27 having the identifying characteristics of the antibody secreted by hybridoma ATCC No. HB 8977.

3. A method for diagnosing prostate tumors and metastases thereof comprising:

(a) obtaining a sample of body fluid from a patient;

(b) exposing the body fluid to a monoclonal antibody as claimed in claim 1 wherein said antibody is secreted by hybridoma TURP-27 with ATCC No. HB 8977;

(c) determining the amount of monoclonal antibody binding to substances present in the body fluid; and

(d) comparing the amount of monoclonal antibody bound to body fluid substances to a predetermined base level to ascertain the presence of prostate tumors or metastases thereof.

4. The method as claimed in claim 3, wherein said body fluid is one member selected from the group consisting of blood, serum, seminal plasma, semen, urine and prostatic fluid.

5. The method as claimed in claim 3, wherein the amount of monoclonal antibody binding to substances present in the body fluid is determined by means of a radioimmunoassay.

6. The method as claimed in claim 3, wherein the amount of monoclonal antibody binding to substances present in the body fluid is determined by means of an enzyme immunoassay.

7. A method for diagnosing the presence of prostate tumors or metastases thereof comprising:

(a) administering to a patient, a monoclonal antibody as claimed in claim 1 wherein said antibody is secreted hybridoma TURP-27 with ATCC No. HB 8977 wherein said monoclonal antibody is conjugated to a marker; and

(b) exposing the patient to a detection device to identify areas of marker corresponding to prostate tumor sites or metastatic sites thereof.

8. The method as claimed in claim 7, wherein the marker is a nuclear magnetic spin-resonance isotope and wherein the detection device is a nuclear magnetic imaging device.

9. The method as claimed in claim 8, wherein the marker is gadolinium.

10. The method as claimed in claim 7, wherein the marker is a radioactive substance and wherein the detection device is a gamma scintillation camera.

11. The method as claimed in claim 10, wherein the radioactive substance is one member selected from the group consisting of I¹²⁵, I¹³¹, I¹²³, In¹¹¹,m In¹¹³, Ga⁶⁷, Ga⁶⁸, Ru⁹⁷, R¹⁰³, Hg¹⁹⁷, Hg²⁰³ and Tc^99m.

12. The method as claimed in claim 11, wherein the radioactive substance is In¹¹¹ or Tc^99M.